Sign In
Sign In
AveXis Inc., the subsidiary that manufactures Zolgensma, brought a “data manipulation issue” related to testing performed on animals to the FDA’s attention five weeks after the drug’s approval. (Photo: Shutterstock)
Recommended Stories
Inflation Reduction Act’s impact on retiree benefits: What employers need to know
As the new law rolls out, some plan sponsors are questioning whether the government’s capabilities to negotiate with Medicare on lower drug prices could prompt manufacturers to increase medication costs for employer plans.
States can address Medicaid inequity by promoting continuity of coverage, study finds
Making it easier for eligible people to enroll in and maintain Medicaid coverage also may help close coverage gaps for people of color.
Top 10 healthiest (and unhealthiest) states in the U.S.
A new study diagnoses the current health of the U.S., revealing which states have taken great strides in reducing health risks—and which ones have a little farther to go.
Resource Center
Case Study
Sponsored by Hello Heart
Client Tool: How One Employer Saved $2,834 Per Participant
Download this case study to share with your clients how they can reduce cardiovascular disease claims costs by implementing an effective digital heart health management program.
Report
Sponsored by Hello Heart
Closing the Gender Gap in Heart Attack Care
Learn how digital health can help close the gender gap in heart attack care.
Case Study
Sponsored by Hello Heart
How VHC Health Saved $2,834 Per Participant
Discover how 1 employer saved >$2,800 per participant!
BenefitsPRO
Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!
- Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
- Exclusive discounts on BenefitsPRO.com and ALM events.
Copyright © 2023 ALM Global, LLC. All Rights Reserved.